Drug intelligence / Profile preview

bivalent human papillomavirus vaccine (Walvax Biotechnology Co., Ltd.)

Development stage: Unknown
Lead developer: Shanghai Zerun Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The bivalent human papillomavirus vaccine (Pichia pastoris), developed by Walvax Biotechnology and its subsidiaries Zerun Biotechnology, is a prophylactic recombinant protein-based vaccine designed to prevent infections caused by HPV types 16 and 18. The vaccine utilizes recombinant L1 virus-like particles (VLPs) expressed in *Pichia pastoris* yeast and is formulated with an aluminum hydroxide adjuvant. It is indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia (CIN grades 2 and 3), and cervical adenocarcinoma in situ in females aged 9 to 30 years. Administered via a three-dose intramuscular schedule (0, 2, and 6 months), it has demonstrated high efficacy and immunogenicity in clinical trials and is approved for use in China.

Brand names: ZerunWozehui
Other names: bivalent human papillomavirus (types 16, 18) vaccine (recombinant, Pichia pastoris)HPV 16/18 vaccine (Pichia pastoris)human papillomavirus bivalent vaccine (recombinant, Pichia pastoris)

Targets

HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))HPV16 (Human papillomavirus type 16)HPV18 L1

Beyond the preview

Go deeper on bivalent human papillomavirus vaccine (Walvax Biotechnology Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalent human papillomavirus vaccine (Walvax Biotechnology Co., Ltd.).

Explore the full profile